MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 18, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...
Q1 Earnings Forecast for INKT Issued By William Blair
Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of MiNK Therapeutics ...
MiNK Therapeutics reports Q4 EPS (62c), consensus (50c)
MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe ...
MiNK Therapeutics (NASDAQ:INKT) Earns “Buy” Rating from HC Wainwright
MiNK Therapeutics (NASDAQ:INKT – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a ...
Business Insider12d
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant ...
De Telegraaf21d
Na zeven jaar ineens jeuk aan je tattoo: waar gaat inkt in je huid eigenlijk naartoe?
Op de Tattoopoli van het Alrijne Ziekenhuis in Leiden wordt geschat dat 90 procent van alle allergieën bij tatoeages komt door rode inkt of kleuren waarin rood is verwerkt. Ongeveer zes procent ...